EXActDNA-003 / NSABP B-64: Breast Cancer Clinical Validation Study to Predict Recurrence of High-Risk Early Breast Cancer Treated With Neoadjuvant Therapy Using a Bespoke Circulating Tumor DNA Assay to Detect Molecular Residual Disease

15573B-64-NCT06401421OpenEXActDNA-003 / NSABP B-64: Breast Cancer Clinical Validation Study to Predict Recurrence of High-Risk Early Breast Cancer Treated With Neoadjuvant Therapy Using a Bespoke Circulating Tumor DNA Assay to Detect Molecular Residual DiseaseNCT06401421IndustrialAdultOtherBreastKurian, ShwetaMedStar Health and GUMC; Medstar Franklin Square Medical Center; Medstar Good Samaritan Hospital; Medstar Montgomery Medical Center; Medstar Southern Maryland Hospital CenterBreastOncology GroupMHRI Oncology Baltimore2026.1.0 Build 16 <a href="https://advarra.com" target="_blank">© 2026 Advarra, Inc.</a>